Loading...
•
Dec 31, 2024
Vertex Q4 2024 Earnings Report
Key Takeaways
Vertex Pharmaceuticals reported strong Q4 2024 results with a 16% increase in product revenue, reaching $2.91 billion, driven by the continued performance of TRIKAFTA/KAFTRIO. However, net income declined slightly due to increased R&D and SG&A expenses.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Vertex expects continued revenue growth in 2025, driven by new product launches such as ALYFTREK and JOURNAVX, alongside further expansion of CASGEVY.
Positive Outlook
- Expected full-year 2025 revenue of $11.75B to $12.0B
- Continued strong demand for TRIKAFTA/KAFTRIO
- Launch of ALYFTREK in the U.S. expected to drive revenue growth
- Expansion of CASGEVY in multiple regions
- Early contributions from JOURNAVX expected
Challenges Ahead
- Higher R&D and SG&A expenses anticipated
- Increased tax rates could impact profitability
- Uncertainty regarding regulatory approvals in some regions
- Potential market competition for CF and pain management drugs
- Macroeconomic factors may affect international sales
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...